Hansoh's B7-H3 ADC wins China breakthrough status for esophageal cancer

Overview

Updated Sep 13

On September 2, 2026, China's drug regulator accepted the first marketing application for Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around the protein B7-H3. The filing covers small cell lung cancer after prior platinum-based chemotherapy and follows a July phase 3 win: the ARTEMIS-008 trial met its primary endpoint of overall survival, making HS-20093 the first B7-H3-directed antibody-drug conjugate to show a survival benefit in any tumor type.

HS-20093, also called risvutatug rezetecan, is licensed to GSK outside Greater China, with a global phase 3 trial in lung cancer expected to read out in 2027. In May, NMPA granted the drug breakthrough status in esophageal squamous cell carcinoma, a disease that kills more people in China than almost anywhere else. A second filing in osteosarcoma is also in preparation after a positive phase 3 readout.

Why it matters

Esophageal cancer kills more people in China than almost anywhere else. Second-line patients have weeks, not years, to live.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

18.5 months

Median overall survival in phase 3 SCLC trial

ARTEMIS-008 met its primary endpoint of overall survival versus topotecan in relapsed small cell lung cancer; Fierce Biotech reported the 18.5-month median.

$1.71B

GSK-Hansoh deal value

GSK paid $185M upfront in December 2023 for global rights to HS-20093 outside Greater China, with milestones worth up to $1.71B.

12+

Total regulatory designations for HS-20093

Includes Breakthrough Therapy, Orphan Drug, and PRIME designations from regulators in China, the US, Europe, and Japan.

First BLA accepted by NMPA

China accepted the small cell lung cancer biologics license application on September 2, 2026, the first filing for HS-20093 anywhere.

~50%

Global esophageal cancer cases in China

China carries roughly half the world's burden of esophageal cancer, most of it squamous cell type.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Zhong Huijuan

Founder and chair, Hansoh Pharmaceutical Group

Steering Hansoh's pivot from generics to innovative oncology

Organizations Involved

Hansoh Pharmaceutical Group

Chinese pharmaceutical company

Developer of HS-20093, the lead B7-H3 ADC in China

Jiangsu-based drugmaker that has shifted from generics to oncology biologics, with antibody-drug conjugates as the main growth bet.

National Medical Products Administration (NMPA)

Chinese drug regulatory agency

Granted HS-20093 breakthrough therapy designation

China's drug and device regulator, the equivalent of the US Food and Drug Administration.

GSK (GlaxoSmithKline)

Pharmaceutical company

Holder of ex-China rights to HS-20093, running global phase 3 trials

British drugmaker that licensed HS-20093 from Hansoh in December 2023 for all markets outside mainland China, Hong Kong, Macau, and Taiwan.

Timeline

March 2021 September 2026

9 events Latest: September 7th, 2026 · 1 month ago

Tap a bar to jump to that date

September 2026
NMPA accepts first BLA for HS-20093 in small cell lung cancer
Latest Regulatory

China's National Medical Products Administration accepted Hansoh's biologics license application for risvutatug rezetecan in adult patients with small cell lung cancer after failure of prior platinum-based chemotherapy. The filing was submitted on September 2, 2026.
September 7th, 2026
July 2026
ARTEMIS-011 meets primary endpoint in osteosarcoma
Clinical Data

The pivotal phase 3 trial met its primary endpoint of progression-free survival in patients with osteosarcoma who progressed after at least two prior lines of therapy. Hansoh said it would start preparing a China biologics license application.
July 28th, 2026
ARTEMIS-008 meets overall survival endpoint in small cell lung cancer
Clinical Data

The pivotal phase 3 trial met its primary endpoint of overall survival in advanced or relapsed small cell lung cancer after prior platinum-based therapy, with statistically significant improvement versus topotecan. This was the first positive phase 3 result for a B7-H3-directed ADC in any tumor type.
July 10th, 2026
May 2026
NMPA grants breakthrough status in esophageal cancer
Regulatory

China's regulator clears HS-20093 for fast-track development in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma who have failed platinum chemotherapy and a PD-1 inhibitor.
May 11th, 2026
March 2025
Daiichi Sankyo posts rival B7-H3 ADC data
Competitive

Daiichi Sankyo's ifinatamab deruxtecan shows similar activity in small cell lung cancer, confirming B7-H3 as a workable target and intensifying the class race.
March 12th, 2025
November 2024
FDA breakthrough designation in osteosarcoma
Regulatory

The US Food and Drug Administration grants HS-20093 breakthrough status for advanced osteosarcoma, a rare bone cancer in children and young adults.
November 5th, 2024
June 2024
First NMPA breakthrough designation
Regulatory

China grants HS-20093 breakthrough therapy status for relapsed small cell lung cancer, the first of several such designations.
June 20th, 2024
December 2023
Strong early data in small cell lung cancer
Clinical Data

HS-20093 posts response rates above 60% in heavily pretreated small cell lung cancer at the San Antonio cancer meeting, a disease where standard chemotherapy responses are usually under 20%.
December 10th, 2023
March 2021
Hansoh files first HS-20093 trial application
Clinical Development

Hansoh starts human trials of HS-20093 in advanced solid tumors. The drug pairs a B7-H3 antibody with a topoisomerase inhibitor payload.
March 15th, 2021

Scenarios

HS-20093 wins NMPA approval for esophageal cancer in 2027

Likely

Discussed by: Chinese sell-side analysts at CITIC Securities and Jefferies oncology team

Hansoh runs a confirmatory phase 3 trial against best supportive care or investigator's choice chemotherapy. With breakthrough status, NMPA accepts rolling submission and clears the drug for late-line use within 12 to 18 months. This is the base case if response rates from the registrational study hold above 30%.

Western pharma licenses HS-20093 in a billion-dollar deal

Possible

Discussed by: Endpoints News and STAT have flagged Chinese B7-H3 assets as the next licensing wave

After Merck paid LaNova Medicines $3.3 billion upfront for a PD-1/VEGF bispecific in 2024 and Western buyers picked up several Chinese ADCs in 2025, HS-20093's growing data package makes it a clear out-licensing target. A deal would give Hansoh upfront cash and a global development partner.

B7-H3 ADC class hits a safety wall in pivotal trials

Possible

Discussed by: Oncology safety reviewers in The Lancet Oncology have flagged interstitial lung disease risk across DXd-payload ADCs

Several antibody-drug conjugates using related payloads have shown rates of interstitial lung disease above 10%. If pivotal data for HS-20093 or its rivals show severe or fatal cases, regulators may add restrictions, slow approvals, or push the class back to later lines.

Daiichi Sankyo's ifinatamab deruxtecan beats HS-20093 to global approval

Possible

Discussed by: Wall Street analysts at Cowen and SVB Securities tracking the B7-H3 race

Daiichi and partner Merck are running registrational trials in small cell lung cancer with deeper resources and global trial networks. They may secure the first US approval in B7-H3 ADCs, defining the commercial benchmark before HS-20093 reaches Western markets.

NMPA approves HS-20093 for small cell lung cancer in 2027

Likely Resolves by End of 2027

Discussed by: Chinese sell-side analysts tracking Hansoh's BLA review timeline

The SCLC BLA was accepted on September 2, 2026 with breakthrough therapy status. If the ARTEMIS-008 overall survival data hold up in review, NMPA approval in 2027 would make HS-20093 the first approved B7-H3-directed ADC in any market, ahead of Daiichi Sankyo's ifinatamab deruxtecan.

GSK's global phase 3 trial sets up first US filing

Likely Resolves by End of 2027

Discussed by: Biospace and Clinical Trials Arena coverage of the GSK-Hansoh partnership

GSK is running the global EMBOLD SCLC-301 trial in relapsed extensive-stage small cell lung cancer, with pivotal data expected in 2027. A positive readout would put HS-20093 on track for US and European filings, positioning GSK against Daiichi Sankyo and Merck in the B7-H3 ADC race.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 2019 to August 2022

Enhertu redefines HER2-positive cancer (2019-2022)

Daiichi Sankyo and AstraZeneca won FDA approval for trastuzumab deruxtecan, branded Enhertu, in HER2-positive breast cancer. Follow-up trials showed it also worked in HER2-low breast cancer and HER2-positive gastric and lung cancers, expanding the addressable population sharply.

Then

Enhertu sales passed $1 billion in 2022 and the drug became standard of care across multiple HER2 settings.

Now

The success validated DXd-payload antibody-drug conjugates as a platform and pulled massive capital into the ADC space, including the Chinese programs now reaching late-stage trials.

Why this matters now

HS-20093 uses the same class of payload chemistry against a different tumor antigen. If B7-H3 expression patterns play out like HER2 did, the drug could move from late-line salvage into earlier treatment settings.

August 2011

Adcetris launches the modern ADC era (2011)

The FDA approved brentuximab vedotin, marketed as Adcetris, for relapsed Hodgkin lymphoma after a single phase 2 trial showed 75% response rates. It was the first commercially successful antibody-drug conjugate after years of failures in the class.

Then

Adcetris reached blockbuster sales within five years and proved that ADCs could be safe and effective when antibody, linker, and payload were properly matched.

Now

The approval kicked off two decades of ADC investment that produced more than 15 approved drugs and hundreds of clinical-stage programs, including the B7-H3 class now advancing in China.

Why this matters now

Like Adcetris, HS-20093 is winning early approvals in narrow, hard-to-treat indications. The Adcetris path shows how that beachhead can expand into a broader franchise if pivotal data hold up.

August 2015 to October 2018

China overhauls drug review and approval (2015-2018)

Beijing restructured its drug regulator, cleared a backlog of pending applications, joined the International Council for Harmonisation, and created a breakthrough therapy pathway modeled on the FDA's. Domestic biotech investment surged from under $1 billion a year to more than $10 billion.

Then

Approval times for innovative drugs in China fell from years to months, and dozens of Chinese biotechs filed first investigational drug applications.

Now

China became the second-largest source of new oncology drug candidates worldwide, with companies like Hansoh, BeiGene, and Innovent building globally competitive pipelines.

Why this matters now

HS-20093's run of breakthrough designations is a direct product of that reform. Without the new NMPA pathway, the drug would likely be three to five years behind in its development timeline.